Video
Author(s):
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
In this video, Brian D. Gonzalez, PhD, discusses the background, findings, and takeaways of the study, “Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gonzalez is an associate member and quality of life researcher at Moffitt Cancer Center in Tampa, Florida.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
SBRT may offer a safe alternative to CFRT after prostatectomy
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy
2 Commerce Drive
Cranbury, NJ 08512